JOSÉ BASELGA. Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
|
|
- Piers Ford
- 5 years ago
- Views:
Transcription
1 The Oncologist Targeting the Phosphoinositide-3 (PI3) Kinase Pathway in Breast Cancer JOSÉ BASELGA Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA Disclosures: José Baselga: Consultant/advisory role: Novartis, Merck, Exelixis. The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the independent peer reviewers. ABSTRACT The phosphoinositide-3 kinase (PI3K) pathway has been identified as an important target in breast cancer research for a number of years, but is new to most clinicians responsible for the daily challenges of breast cancer management. In fact, the PI3K pathway is probably one of the most important pathways in cancer metabolism and growth. Mutations in the PI3K pathway are frequent in breast cancer, causing resistance to human epidermal growth factor receptor 2 targeted agents and, possibly, to hormonal agents as well. Available agents that affect the PI3K pathway include monoclonal antibodies and tyrosine kinase inhibitors, as well as PI3K inhibitors, Akt inhibitors, rapamycin analogs, and mammalian target of rapamycin (mtor) catalytic inhibitors. Multiple PI3K inhibitors are currently under development, including pure PI3K inhibitors, compounds that block both PI3K and mtor (dual inhibitors), pure catalytic mtor inhibitors, and inhibitors that block Akt. It is likely that these agents will have to be given in combination with other signal inhibitors because anti-mtor agents and PI3K inhibitors may result in the activation of compensatory feedback loops that would in turn result in decreased efficacy. This article reviews current data related to the PI3K pathway, its role in breast cancer, the frequency with which PI3K is aberrant in breast cancer, and the potential clinical implications of using agents that target the PI3K pathway. The Oncologist 2011;16(suppl 1):12 19 INTRODUCTION The phosphoinositide-3 kinase (PI3K) pathway has been identified as an important target in breast cancer research for a number of years, but could be unfamiliar to clinicians responsible for daily breast cancer management. This article reviews the current data related to the PI3K pathway, its role in breast cancer, how frequently PI3K is aberrant in breast cancer, and the potential clinical implications of these findings with the use of agents that target the PI3K pathway. AN OVERVIEW OF THE PI3K PATHWAY The PI3Ks are a family of lipid kinases whose primary biochemical function is to phosphorylate the 3-hydroxyl group of phosphoinositides [1]. Class IA PI3Ks, deregulated in cancer, are heterodimers comprised of a regulatory subunit (referred to as p85) and a catalytic subunit (p110). Activation of PI3Ks is initiated when a growth factor or ligand binds to its cognate receptor tyrosine kinase (RTK). These receptors include members of the human epidermal growth factor receptor (HER) family, and the insulin and insulin- Correspondence: José Baselga, M.D., Ph.D., Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston, Massachusetts 02114, USA. Telephone: ; Fax: ; jbaselga@partners.org, AlphaMed Press /2011/$30.00/0 doi: /theoncologist.2011-S1-12 The Oncologist 2011;16(suppl 1):
2 Baselga 13 Figure 1. PI3K pathway mutations in cancer. Abbreviations: BAD, Bcl-2-associated death promoter; GRB2, growth factor receptor-bound protein 2; IRS1, insulin receptor substrate 1; MDM2, murine double minute 2; mtor, mammalian target of rapamycin; PDK1, 3-phosphoinositide-dependent protein kinase 1; PI3K, phosphoinositide-3 kinase; PIP2, phosphatidylinositol bisphosphate; PIP3, phosphatidylinositol triphosphate; PTEN, phosphatase and tensin homologue deleted on chromosome ten; RAPTOR, regulatory associated protein of TOR; RICTOR, rapamycin-insensitive companion of mammalian target of rapamycin; TSC, tuberous sclerosis. like growth factor 1 receptor (IGF-1R), among others. Upon receptor activation, the PI3K heterodimer interacts with their intracellular portion via p85. Alternatively, an adaptor molecule may act as an intermediary between an RTK and p85, such as occurs with insulin receptor substrate 1 (IRS1) downstream of IGF-1R. Binding removes the inhibitory effect of p85 on p110, resulting in full activation of PI3K. The activated kinase catalyses the phosphorylation of phosphatidylinositol bisphosphate (PIP2) to phosphatidylinositol triphosphate (PIP3). PIP3 acts as a docking site for Akt, a serine/threonine kinase that is the central mediator of the PI3K pathway, and phosphoinositide-dependent kinase 1. Once localized at the cell plasma membrane, Akt is phosphorylated and stimulates protein synthesis and cell growth by activating mammalian target of rapamycin (mtor) through effects on the intermediary tuberous sclerosis 1/2 complex. The PI3K pathway is integral to diverse cellular functions, including cellular metabolism and proliferation, differentiation, and survival (Fig. 1). Additional evidence of the importance of this pathway is the high frequency with which and the multiple sites where this pathway is aberrantly hyperactivated in cancer, as illustrated in Figure 1, which shows locations in the pathway where activating mutations and deletions have been identified. In addition to the activating components of the pathway, some of the components of the pathway have an intrinsic inhibitory effect, such as phosphatase and tensin homologue deleted on chromosome ten (PTEN), for example [2]. PTEN loss activates the pathway, because PTEN has been charged with the reconversion of PIP3 into PIP2. Mutations also occur at the level of RTK receptors, mutations in PTEN itself, Akt, and Ras, among others. THE PI3K PATHWAY IN BREAST CANCER The PI3K pathway is frequently aberrantly activated in breast cancer with mutations occurring in up to one quarter of breast cancers. The majority of mutations are in PIK3CA, encoding the catalytic p110 subunit, and are nonrandomly localized in three hot spots, resulting in single amino acid
3 14 Targeting PI3K in Breast Cancer Table 1. Frequency of mutations in the PIK3CA and PTEN genes in 547 human breast cancers Mutation Breast cancer subtype PIK3CA catalytic domain * PIK3CA other PIK3CA total PTEN All breast tumors 73/547 (13.3%) 44/547 (8.0%) 117/547 (21.4%) 2/88 (2.3%) HR 48/232 (20.7%) 32/232 (13.8%) 80/232 (34.5%) 2/58 (3.4%) ER PR 39/186 (21%) 22/186 (11.8%) 61/186 (32.8%) 1/48 (2.1%) ER PR 9/41 (22%) 10/41 (24.4%) 19/41 (46.3%) 1/8 (12.5%) ER PR 0/5 (0%) 0/5 (0%) 0/5 (0%) 0/2 (0%) HER2 13/75 (17.3%) 4/75 (5.3%) 17/75 (22.7%) 0/10 (0%) Triple negative 12/240 (5.0%) 8/240 (3.3%) 20/240 (8.3%) 0/20 (0%) From Stemke-Hale K, Gonzalez-Angulo AM, Lluch A et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008;68: , with permission. substitutions: E545K and E542K in the helical domain (exon 9) and H1047R in the kinase domain (exon 20). These mutations increase enzymatic function, enhance downstream signaling elements including Akt, and promote oncogenic transformation. Overall, the proportion of breast tumors exhibiting these mutations is in the range of 20% 25%, depending on the breast cancer subtype. For example, in hormone receptor positive tumors, these mutations occur in 30% of cases. Also, in HER2 disease, mutations are evident in about one quarter of tumors. Meanwhile, it seems that mutations in triple-negative breast cancer may be less frequent [3] (Table 1). It is important to note that, as more data series are gathered, these numbers could change, but these data trends offer an initial picture on the distribution of these mutations in the different subtypes of breast cancer. As shown in Table 1, PTEN alterations have been described as well, but may be less common. Mutations or amplifications in oncogenes are frequently associated with adverse outcomes, the classical example of which has been HER2 amplification. The relationship between PI3K mutation status and clinical outcome is now being studied. In an initial study, investigators at Memorial Sloan Kettering Cancer Center identified that PI3KCA mutations are associated with favorable clinicopathologic features and better clinical outcomes, including survival benefits [4]. Consequently, clinical data with PI3K inhibitors and with mtor inhibitors need to be evaluated carefully with respect to historical series, because patients with these tumors could have a better outcome. The corollary of this, though, is that if these patients intrinsically have a less aggressive form of the disease, it could well be that a less aggressive therapy, including PI3K inhibitors and hormonal therapies, should be considered. On the other hand, PI3K mutations may also play a role in resistance to some of the therapies that block upstream tyrosine kinase receptors. For example, PI3K mutations have been implicated as a mechanism of resistance to anti- HER2 agents. One study looked at PTEN status and PI3K mutation status in patients who had been treated with trastuzumab. Tumors with the PTEN deletion of PI3K mutations responded less efficiently to trastuzumab, which suggests a mechanism of trastuzumab resistance in HER2 breast cancer [5]. This finding is not surprising, because trastuzumab blocks the signaling pathway upstream from PI3K. If a downstream mutation exists, it would override upstream inhibition. In laboratory experiments, a genomewide small hairpin RNA screen was used to determine potential mediators of resistance to lapatinib, a small tyrosine kinase receptor of HER2. In these assays, PTEN deletion resulted in lapatinib resistance. One experiment was conducted in cells with different levels of PTEN and PI3K expression, as well as control cells with wild-type PTEN and wild-type PI3K. The bottom of Figure 2 illustrates cells with p110 overexpression and cells with the two frequent PI3K hotspot mutations. All cells were treated with either trastuzumab, lapatinib, or a combination of the two. As evidenced in the figure, cells harboring PI3K mutations or the PTEN deletion were clearly resistant to both trastuzumab and lapatinib [6] (Fig. 2). Evidence also exists to suggest that PI3K mutations may confer resistance to hormonal therapy. In support of this, hyperactivation of receptors that signal via the PI3K pathway, such as HER1, HER2, and insulin like growth factor receptor (IGFR) also result in resistance to antiestrogen therapy [7]. The proposed mechanism of resistance is via direct induction of estrogen receptor (ER) transcription (Fig. 3). Additional studies have demonstrated that PI3K
4 Baselga 15 Figure 2. Hyperactivation of the PI3K pathway regulates trastuzumab and lapatinib sensitivity in HER2 breast cancer cells. Abbreviations: HER2, human epidermal growth factor receptor 2; PI3K, phosphoinositide-3 kinase; PTEN, phosphatase and tensin homologue deleted on chromosome ten. From Eichhorn PJ, Gili M, Scaltriti M et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mtor/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 2008;68: , with permission. mutations could also mediate resistance to downstream mtor inhibitors. AGENTS TARGETING PI3K The first agents against the pathway that were studied in the clinic were rapamycin analogs. These agents work by interfering with mtorc1, which is the complex formed by mtor and regulatory associated protein of TOR. Clinical data are now available to suggest that mtor inhibition may play a role in the therapy of breast cancer. In a neoadjuvant randomized phase II study in patients with newly diagnosed, primary ER breast tumors 2 cm, patients were randomized to receive either letrozole plus placebo for 16 weeks or letrozole plus daily everolimus (RAD001), a rapamycin analog. The primary endpoint of the trial was response to the combination therapy [8]. Patients who received the rapamycin analog had a better response rate, which provided a clear indication that the mtor inhibitor may be a potential novel addition to the therapy of breast cancer. Because a decrease in the proliferation marker Ki67 has been proposed as a valid surrogate marker of clinical benefit to antihormonal agents in the neoadjuvant setting, investigators also analyzed changes in Ki67 in the two therapy groups. Baseline distributions of Ki67 values were similar in the treatment arms. Using the definition that patients with a ln(ki67) 1 at day 15 had an antiproliferative response, 57% of everolimus-treated patients were responders, compared with 30% of placebo-treated patients (p.01) (Fig. 4). This finding suggested that the combination is more efficient at blocking proliferation and correlates with the observed greater clinical benefit of the combination treatment. Based on these data, a number of ongoing phase III studies are exploring the efficacy of everolimus in patients with metastatic ER breast cancer. Although fewer data are available with trastuzumab and mtor blockade, a phase I study was conducted in patients who were largely resistant to paclitaxel and had prior exposure to trastuzumab. With the addition of everolimus, the activity demonstrated was quite remarkable [9]. Based on these findings, additional studies are being conducted in the HER2 metastatic setting. Meanwhile, an important pharmacodynamic finding in the initial metastatic and neoadjuvant studies was the observation that, upon mtor blockade with everolimus, there was an increase in the activated phosphorylated form of Akt (pakt). Figure 5 shows Akt phosphorylation status prior to and during therapy, demonstrating an increase in pakt in everolimus-treated patients [10] (Fig. 5). We had identified a potential explanation for what was at first a counterintuitive finding: S6, a molecule that is immediately downstream from and activated by mtor, suppresses signaling of IGF-1R via suppression of IRS1. The blockade of mtor and the resulting inhibition of S6 causes a negative feedback loop effect, and IGF-1R becomes activated, which in turns results in increased PI3K signaling and activation of Akt (Fig. 6). The activation of this compensatory pathway (Fig. 7) could be, in part, responsible for the limited activity that this class of agents has shown against breast cancer to date [11]. In preclinical models, the activation of this compensatory pathway is totally prevented by anti-igf-1r monoclonal antibodies and there is strong evidence that combining anti IGF-1R monoclonal antibodies and mtor inhibitors results in synergism [12]. This combination is currently being explored in a phase I clinical trial, and remarkable activity has been observed in patients with ER luminal B breast cancer [13]. Another equally appealing approach would be the use of PI3K inhibitors in combination with mtor inhibitors. PI3K INHIBITORS UNDER CLINICAL DEVELOPMENT Current PI3K inhibitors under development are grouped by their specificity, ranging from pure PI3K inhibitors, to compounds that block both PI3K and mtor (dual inhibitors), to pure catalytic mtor inhibitors, and to inhibitors that block Akt. Two agents that are discussed in further detail here are the compounds being developed by Exelixis and sanofi-aventis: XL147 and XL765. The XL147 agent is a selective PI3K inhibitor. This compound is a potent inhibitor of the Class I PI3K family.
5 16 Targeting PI3K in Breast Cancer Figure 3. Strategies to overcome resistance in hormone receptor positive breast cancer. Abbreviations: CBP, CREB binding protein; ER, estrogen receptor; ERE, estrogen-responsive element; HER2, human epidermal growth factor receptor 2; MAPK, mitogen-activated protein kinase; MEK, mitogen-activated protein kinase/extracellular signal related kinase kinase; mtor, mammalian target of rapamycin; PI3K, phosphoinositide-3 kinase; SOS, son of sevenless. From Di Cosimo S, Baselga J. Management of breast cancer with targeted agents: Importance of heterogenicity. Nat Rev Clin Oncol 2010;7: , with permission. Figure 4. Phase 2 neoadjuvant everolimus (RAD001) breast cancer study: Change in Ki67. The agent, which can be administered orally, does not inhibit mtor or the mitogen-activated protein kinase/extracellular signal related kinase kinase pathway, and has demonstrated preclinical efficacy in PI3K, PTEN, and KRAS mutant xenografts. Initial phase I studies have demonstrated an adequate safety profile. In a single-agent dose-escalation study, two XL147 dosing schedules were investigated. These include 20 days on and 7 days off (21/7) and a continuous daily schedule. The first study also included a cohort expansion in patients with non-small cell lung cancer (NSCLC) and lymphoma [14]. A second study in NSCLC patients is being expanded, combining XL147 with erlotinib [15]. A third study is combining XL147 with paclitaxel and carboplatin, with cohort expansions in patients with endometrial cancer, ovarian cancer, and NSCLC [16]. In the first study, 48 patients were enrolled by the time
6 Baselga 17 Figure 5. The mtor inhibitor everolimus increases tumor pakt in breast cancer patients. From Tabernero J, Rojo F, Calvo E et al. Dose- and scheduledependent inhibition of the mammalian target of rapamycin pathway with everolimus: A phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008;26: Reprinted with permission American Society of Clinical Oncology. All rights reserved. Figure 6. mtor represses IRS1 under basal conditions. Abbreviations: IGF1-R, insulin-like growth factor 1 receptor; IRS1, insulin receptor substrate 1; mtor, mammalian target of rapamycin; PDK1, 3-phosphoinositide-dependent protein kinase 1; PI3K, phosphoinositide-3 kinase; PIP2, phosphatidylinositol bisphosphate; PIP3, phosphatidylinositol triphosphate; PTEN, phosphatase and tensin homologue deleted on chromosome ten; RAPTOR, regulatory associated protein of TOR; RICTOR, rapamycin-insensitive companion of mammalian target of rapamycin; TSC, tuberous sclerosis. data were presented at the 2009 annual meeting of the American Society of Clinical Oncology (ASCO). A maximum-tolerated dose (MTD) of 600 mg was determined for Figure 7. Activation of IRS1 and Akt by mtor inhibitors is prevented by the co-administration of anti-igf-1r monoclonal antibodies. Abbreviations: IGF1-R, insulin-like growth factor 1 receptor; IRS1, insulin receptor substrate 1; mtor, mammalian target of rapamycin; PDK1, 3-phosphoinositide-dependent protein kinase 1; PI3K, phosphoinositide-3 kinase; PIP2, phosphatidylinositol bisphosphate; PIP3, phosphatidylinositol triphosphate; PTEN, phosphatase and tensin homologue deleted on chromosome ten; RAPTOR, regulatory associated protein of TOR; RICTOR, rapamycin-insensitive companion of mammalian target of rapamycin; TSC, tuberous sclerosis. the 21/7 dosing schedule. The trial is still ongoing with continuous daily dosing. A dose-limiting toxicity of rash was reported. For the most part, however, the compound is well tolerated. There is excellent pharmacodynamic clinical evidence of inhibition of the pathway, in addition to evidence of clinical activity [14]. Clinical responses have been reported in a patient with NSCLC and also in a proportion of patients with longstanding, stable disease 12 weeks. Interestingly, the compound also inhibits extracellular signal related kinase (ERK) signaling, as seen by immunochemistry [14]. Inhibition of ERK signaling is not seen with mtor inhibitors, which actually activate the perk pathway, and likewise has not been reported with other PI3K inhibitors. Potential mechanisms leading to this lack of ERK activation are unknown. Another compound, XL765, is a dual mtor and PI3K in-
7 18 Targeting PI3K in Breast Cancer hibitor. In terms of mtor inhibition, this is a catalytic inhibitor of TORC1 and TORC2, as opposed to the rapamycin analogs described above that target solely TORC1. Like XL147, the agent is designed for oral administration and has demonstrated clinical efficacy in a variety of models. There are a number of phase I clinical trials currently under way with XL765. The first study is looking at different dosing schedules daily or twice a day [17]. Other studies are investigating XL765 in combination with temozolomide in glioblastoma multiforme patients [18], and in combination with erlotinib, with expansions in NSCLC patients [19]. At the time of the last report at the 2009 ASCO meeting, 51 patients had been enrolled. An MTD of 50 mg twice daily was identified, and the first study is still enrolling on a daily schedule. With XL765, dose-limiting toxicities have included transaminase elevations at higher dose levels. These were reversible and not seen at lower levels. Excellent pharmacodynamic activity has been observed in normal and tumor tissue, and some evidence of clinical antitumor activity has been observed as well, including in patients with KRAS-mutant colorectal cancer. Impressive inhibition of the pathway was seen by examining pakt and pebp1. Similar findings were also observed with respect to ERK inhibition. Based on these promising initial clinical data, phase II studies are now open or about to be open to enrollment for patients with ER /progesterone receptor (PR) breast cancer, and in those with HER2 disease. Although these trials will initially enroll a wide patient population, potential enrollees will eventually undergo real-time advanced tumor genotyping in order to select for patients with tumors with either PI3K mutations or PTEN deletions. Hence, it is anticipated that a number of patients in each cohort will have PI3K mutations, so that patients with a higher likelihood of benefiting may be included in the study. A phase I/II randomized study of letrozole and XL147 versus letrozole and XL765 is also planned. This interesting design will pose the question of whether it is better to inhibit PI3K alone or PI3K and mtor when given in combination with hormonal therapy. Although the study design was still under discussion at the time of this presentation, it is likely that the phase I study will be a classical 3 3 dose escalation, and then the phase II study will have 50 patients accrue to each arm. The key eligibility criteria will include postmenopausal patients with ER PR tumors with metastatic breast cancer. Eligible patients will also be refractory to a nonsteroidal aromatase inhibitor. The primary objective of the phase I study is to determine the MTD; the phase II objective will be the objective response rate and progressionfree survival rate at 3 months. Another phase I/II study is planned with XL147 in patients who have received trastuzumab and who have failed to respond to treatment. One treatment arm will consist of XL147 in combination with trastuzumab, and the other treatment arm will consist of XL147 in combination with trastuzumab and paclitaxel. The phase I and phase II studies will each accrue 25 patients to each arm and are being conducted with the goal of answering important therapeutic questions. The primary endpoint of the phase I study is the MTD of XL147 in combination with each regimen (trastuzumab or trastuzumab plus paclitaxel). The phase II primary endpoint is the objective response rate. Eligible patients will have metastatic HER2 breast cancer, and will have progressed on at least one prior trastuzumab-containing regimen. Tumor biopsies will be requested in the phase II trial, when feasible. CONCLUSIONS Mutations in the PI3K pathway are frequent in breast cancer and result in resistance to HER2-targeted agents and, possibly, to hormonal agents as well. Anti-mTOR agents have clinical activity against breast cancer, but activation of feedback loops may result in decreased efficacy. In phase I studies, the PI3K inhibitors XL147 and XL765 have been shown to effectively block the PI3K and ERK pathways, and they have demonstrated signs of clinical activity. Phase II clinical trials with XL147 are under way in two settings in hormone-refractory disease and also in patients who have failed trastuzumab. Trial results are awaited to determine the role of these new agents in clinical practice. REFERENCES 1 Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002;296: Wellcome Trust Sanger Institute. Catalogue of Somatic Mutations in Cancer (COSMIC). Available at: cosmic/, accessed March 9, Stemke-Hale K, Gonzalez-Angulo AM, Lluch A et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008;68: Kalinsky K, Jacks LM, Heguy A et al. PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res 2009;15: Berns K, Horlings HM, Hennessy BT et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007;12: Eichhorn PJ, Gili M, Scaltriti M et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mtor/ phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 2008; 68:
8 Baselga 19 7 Di Cosimo S, Baselga J. Management of breast cancer with targeted agents: Importance of heterogenicity. Nat Rev Clin Oncol 2010;7: Baselga J, Semiglazov V, van Dam P et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009;27: André F. Multicenter phase I clinical trial of daily and weekly RAD001 in combination with weekly paclitaxel and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab. J Clin Oncol 2008;26(suppl): Atzori F, Tabernero J, Cervantes A et al. A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qw) MK-0646, an insulinlike growth factor-1 receptor (IGF1R) monoclonal antibody (MAb) in patients (pts) with advanced solid tumors. J Clin Oncol 2008; 26(15 suppl): Tabernero J, Rojo F, Calvo E et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: A phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008;26: Di Cosimo S, Scaltriti M, Val D et al. The PI3-K/AKT/mTOR pathway as a target for breast cancer therapy. J Clin Oncol 2007;25(suppl 18): Di Cosimo S, Bendell JC, Cervantes-Ruiperez et al. A phase I study of the oral mtor inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotozumab (DALO) in patients (pts) with advanced solid tumors. J Clin Oncol 2010;28(15 suppl): Shapiro G, Kwak E, Baselga J et al. Phase I dose-escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumors. J Clin Oncol 2009;27(15 suppl): Faulkner N, LoRusso PM, Guthrie T et al. A phase 1 safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with erlotinib in patients with advanced solid tumors. Mol Cancer Ther 2009;8(suppl 1):C Wheler JJ, Traynor AM, Bailey HH et al. A phase 1 safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with paclitaxel (P) and carboplatin (C) in patients with advanced solid tumors. Mol Cancer Ther 2009;8(suppl 1):B LoRusso P. A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765, a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced solid tumors. J Clin Oncol 2009;27(15 suppl): Wen PY, Omuro AM, Batchelor TT et al. A Phase 1 safety and pharmacokinetic study of XL765 (SAR245409), a novel PI3K/TORC1/TORC2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with malignant glioma. Mol Cancer Ther 2009;8(suppl 1):B Janne PA, Felip E, Cedres S et al. A phase 1 safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor, XL765 (SAR245409), in combination with erlotinib in patients (pts) with advanced solid tumors. Mol Cancer Ther 2009;8(suppl 1):A254.
The PI3K/AKT axis. Dr. Lucio Crinò Medical Oncology Division Azienda Ospedaliera-Perugia. Introduction
The PI3K/AKT axis Dr. Lucio Crinò Medical Oncology Division Azienda Ospedaliera-Perugia Introduction Phosphoinositide 3-kinase (PI3K) pathway are a family of lipid kinases discovered in 1980s. They have
More informationJosé Baselga, MD, PhD
i n t e r v i e w José Baselga, MD, PhD Dr Baselga is Physician-in-Chief at Memorial Sloan-Kettering Cancer Center in New York, New York. Tracks 1-15 Track 1 Track 2 Track 3 Track 4 Track 5 Track 6 Track
More informationMultimedia Appendix 6 Educational Materials Table of Contents. Intervention Educational Materials Audio Script (version 1)
Multimedia Appendix 6 Educational Materials Table of Contents Intervention Educational Materials... 1 Audio Script (version 1)... 1 Text (version 1)... 5 Slides (version 1)... 17 Audio Script (version
More informationPhospho-PRAS40 Thr246 predicts trastuzumab response in patients with HER2-positive metastatic breast cancer
ONCOLOGY LETTERS 9: 785-789, 2015 Phospho-PRAS40 Thr246 predicts trastuzumab response in patients with HER2-positive metastatic breast cancer KAI YUAN, HONGYAN WU, YULONG WANG, HONGQIANG CHEN, MINGWEN
More informationPIK3CA Mutations in HER2-Positive Breast Cancer
2016.4.29. GBCC PIK3CA Mutations in HER2-Positive Breast Cancer Seock-Ah Im, MD, PhD. Department of Internal Medicine Seoul National University Hospital Contents Introduction TCGA data HER2 signaling pathway
More informationmtor e le altre vie di trasduzione del segnale: Implicazioni cliniche Giampaolo Tortora
mtor e le altre vie di trasduzione del segnale: Implicazioni cliniche Giampaolo Tortora Cattedra di Oncologia Medica UOC Oncologia Medica du Facoltà di Medicina e Chirurgia e Azienda Ospedaliera Universitaria
More informationA particular set of insults induces apoptosis (part 1), which, if inhibited, can switch to autophagy. At least in some cellular settings, autophagy se
A particular set of insults induces apoptosis (part 1), which, if inhibited, can switch to autophagy. At least in some cellular settings, autophagy serves as a defence mechanism that prevents or retards
More informationResistance to anti-her2 therapies. Service d Oncologie Médicale
Resistance to anti-her2 therapies Pr David Khayat Service d Oncologie Médicale Groupe Hospitalier Pitié Salpêtrière -Paris Disclosure statment Trastuzumab in HER2+ MBC A major impact but resistance will
More informationLAPATINIB-Resistance to small Molecule ErbB2 Tyrosine Kinase Inhibitor (TKI)
LAPATINIB-Resistance to small Molecule ErbB2 Tyrosine Kinase Inhibitor (TKI) Prim Mr Sc Dr Suzana Vasović Institute for oncology and radiology of Serbia UMOS, X Conference, 16.05.2015 Belgrade How do we
More informationChallenges in the clinical development of PI3K inhibitors
Ann. N.Y. Acad. Sci. ISSN 0077-8923 ANNALS OF THE NEW YORK ACADEMY OF SCIENCES Issue: Inositol Phospholipid Signaling in Physiology and Disease Challenges in the clinical development of PI3K inhibitors
More informationMechanisms of Resistance to. Lisa A. Carey, M.D. University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center
Mechanisms of Resistance to Hormonal Therapy Lisa A. Carey, M.D. University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center Antagonizing Estrogen Dependent Growth Premenopausal
More informationTargeting mtor pathway in ER+/Her2- breast cancers. Fabrice ANDRE Gustave Roussy
Targeting mtor pathway in ER+/Her2- breast cancers Fabrice ANDRE Gustave Roussy Outline mtor pathway Clinical development of rapalogs in breast cancer Moving beyond rapalogs mtor pathway LKB1 Ras-raf-
More information10/15/2012. Overcoming Endocrine Therapy Resistance. The Problem in ER+ Tumors is Endocrine Therapy Resistance
Overcoming Endocrine Therapy Resistance Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology Slide Credits: Hope Rugo, MD The Problem in ER+ Tumors is Endocrine Therapy Resistance
More informationEGFR: fundamenteel en klinisch
EGFR: fundamenteel en klinisch Guido Lammering MAASTRO Clinic Maastricht, NL What is EGFR?? The EGFR some facts 1186 amino acids 170 kda Expressed by all cells of epithelial origin Increased activation
More informationLa via del segnale PI3K/AKT/mTOR Inibitori di mtor nel carcinoma mammario
La via del segnale PI3K/AKT/mTOR Inibitori di mtor nel carcinoma mammario Alessandra Modena U.O.C. Oncologia Medica Direttore: Dott.ssa Stefania Gori Ospedale Sacro Cuore - Don Calabria 29 novembre 2016
More informationNovel Strategies in Systemic Therapies: Overcoming Endocrine Therapy Resistance
Novel Strategies in Systemic Therapies: Overcoming Endocrine Therapy Resistance Richard S. Finn, MD Division of Hematology/ Oncology Director, Translational Oncology Laboratory Geffen School of Medicine
More informationRadiation therapy Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. Chemotherapy Chemotherapy is a cancer
More informationMechanisms of hormone drug resistance
Mechanisms of hormone drug resistance Ljiljana Stamatović Institute for Oncology and Radiology of Serbia Tenth UMOS Conference, Belgrade, 16-17 th May 2015. Hormone receptor-positive breast cancer (HR+
More informationAdvanced HER2+ Breast Cancer: New Options and How to Deploy Them. José Baselga MD, PhD
Advanced HER2 Breast Cancer: New Options and How to Deploy Them José Baselga MD, PhD HER2 signaling results in a multitude of cellular effects, including increased cellular proliferation HER2 HER3 RAS
More informationTargeting the ERBB family in cancer: couples therapy
OPINION Targeting the ERBB family in cancer: couples therapy Niall Tebbutt, Mikkel W. Pedersen and Terrance G. Johns Abstract The ERBB family of receptor tyrosine kinases has a central role in the tumorigenesis
More informationTargeting the PI3K/Akt/mTOR Pathway Beyond Rapalogs
/ Oncotarget, November, Vol.1, No 7 Targeting the PI3K/Akt/mTOR Pathway Beyond Rapalogs Ben Markman 1, Rodrigo Dienstmann 2, Josep Tabernero 2 1 Centre for Cancer Research, Monash Institute of Medical
More informationReceptor mediated Signal Transduction
Receptor mediated Signal Transduction G-protein-linked receptors adenylyl cyclase camp PKA Organization of receptor protein-tyrosine kinases From G.M. Cooper, The Cell. A molecular approach, 2004, third
More informationTargeting the PI3K-Akt-mTOR pathway with GDC-0068, a novel selective ATP competitive Akt inhibitor
Targeting the PI3K-Akt-mTOR pathway with GDC-0068, a novel selective ATP competitive Akt inhibitor Josep Tabernero, Andrés Cervantes, Cristina Saura, Desamparados Roda, Yibing Yan, Kui Lin, Sumati Murli,
More informationPage. Objectives: Hormone Therapy Resistance: Challenges and Opportunities. Research Support From Merck
Hormone Therapy Resistance: Challenges and Opportunities Pamela. N. Munster, MD University of California, San Francisco Financial Disclosures Research Support From Merck Objectives: Understanding the current
More informationEnzyme-coupled Receptors. Cell-surface receptors 1. Ion-channel-coupled receptors 2. G-protein-coupled receptors 3. Enzyme-coupled receptors
Enzyme-coupled Receptors Cell-surface receptors 1. Ion-channel-coupled receptors 2. G-protein-coupled receptors 3. Enzyme-coupled receptors Cell-surface receptors allow a flow of ions across the plasma
More informationLooking Beyond the Standard-of- Care : The Clinical Trial Option
1 Looking Beyond the Standard-of- Care : The Clinical Trial Option Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health Cancer Center at Orlando Health Professor
More informationBreast Cancer: the interplay of biology, drugs, radiation. Prof. L. Livi Università degli Studi di Firenze. Brescia, October 3rd 4th, 2013
Breast Cancer: the interplay of biology, drugs, radiation Prof. L. Livi Università degli Studi di Firenze Brescia, October 3rd 4th, 2013 BACKGROUND (1) The complex interactions between tumor-specific signaling
More informationKEY CONCEPT QUESTIONS IN SIGNAL TRANSDUCTION
Signal Transduction - Part 2 Key Concepts - Receptor tyrosine kinases control cell metabolism and proliferation Growth factor signaling through Ras Mutated cell signaling genes in cancer cells are called
More informationG-Protein Signaling. Introduction to intracellular signaling. Dr. SARRAY Sameh, Ph.D
G-Protein Signaling Introduction to intracellular signaling Dr. SARRAY Sameh, Ph.D Cell signaling Cells communicate via extracellular signaling molecules (Hormones, growth factors and neurotransmitters
More informationCLINICAL UPDATE ON K-RAS
CLINICAL UPDATE ON K-RAS TARGETED THERAPY IN GASTROINTESTINAL CANCERS S. PA N T, 1 J. H U B B A R D, 2 E. M A RT I N E L L I, 3 A N D T. B E K A I I - S A A B 4 SELECTED HIGHLIGHTS 1 Department of Investigational
More informationEGFR Antibody. Necitumumab, LY , IMC-11F8. Drug Discovery Platform: Cancer Cell Signaling
EGFR Antibody Necitumumab, LY3012211, IMC-11F8 Derived from Yarden Y and Shilo BZ 1 ; Schneider MR and Wolf E. 2 Drug Discovery Platform: Cancer Cell Signaling A Single-Arm, Multicenter, Open-Label, Phase
More informationDiabetes Mellitus and Breast Cancer
Masur K, Thévenod F, Zänker KS (eds): Diabetes and Cancer. Epidemiological Evidence and Molecular Links. Front Diabetes. Basel, Karger, 2008, vol 19, pp 97 113 Diabetes Mellitus and Breast Cancer Ido Wolf
More informationDAVAOncology, LP...facilitating successful drug development
DAVAOncology, L Tyrosine Receptor Kinase I3K p85 p110 TEN TORC1 RAS I2 I3 Efficacy of targeted therapy is challenged by the complexity of tumor biology, including cross talk and redundancies between divergent
More informationGenomic tests to personalize therapy of metastatic breast cancers. Fabrice ANDRE Gustave Roussy Villejuif, France
Genomic tests to personalize therapy of metastatic breast cancers Fabrice ANDRE Gustave Roussy Villejuif, France Future application of genomics: Understand the biology at the individual scale Patients
More informationConcise Reference. HER2 Testing in Breast Cancer. Mary Falzon, Angelica Fasolo, Michael Gandy, Luca Gianni & Stefania Zambelli
Concise Reference Testing in Breast Cancer Mary Falzon, Angelica Fasolo, Michael Gandy, Luca Gianni & Stefania Zambelli Extracted from Handbook of -Targeted Agents in Breast Cancer ublished by Springer
More informationDevelopment of Rational Drug Combinations for Oncology Indications - An Industry Perspective
Development of Rational Drug Combinations for Oncology Indications An Industry Perspective Stuart Lutzker, MDPhD Vice President Oncology Early Development Genentech Inc 1 Conventional Oncology Drug Development
More informationCorporate Medical Policy
Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer
More informationOpen Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD
Open Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD Hanahan and Weinberg, 2000 Acquired Capabilities of Cancer Clinical Trials When should I consider a clinical trial? How do I find the right
More information2014 San Antonio Breast Cancer Symposium Review
2014 San Antonio Breast Cancer Symposium Review HER2 Positive Disease 01-10-2015 Elisavet Paplomata, MD Assistant Professor Hematology & Medical Oncology Emory University Winship Cancer Institute S6-01
More informationALK Fusion Oncogenes in Lung Adenocarcinoma
ALK Fusion Oncogenes in Lung Adenocarcinoma Vincent A Miller, MD Associate Attending Physician, Thoracic Oncology Service Memorial Sloan-Kettering Cancer Center New York, New York The identification of
More informationLecture #27 Lecturer A. N. Koval
Lecture #27 Lecturer A. N. Koval Hormones Transduce Signals to Affect Homeostatic Mechanisms Koval A. (C), 2011 2 Lipophilic hormones Classifying hormones into hydrophilic and lipophilic molecules indicates
More informationA vision for HER2 future
School of Medical Oncology Department of Medical and Biological Sciences - University of Udine Department of Oncology - University Hospital of Udine A vision for HER2 future Current therapeutic algorithm
More informationSignaling. Dr. Sujata Persad Katz Group Centre for Pharmacy & Health research
Signaling Dr. Sujata Persad 3-020 Katz Group Centre for Pharmacy & Health research E-mail:sujata.persad@ualberta.ca 1 Growth Factor Receptors and Other Signaling Pathways What we will cover today: How
More informationXII Michelangelo Foundation Seminar
XII Michelangelo Foundation Seminar The opportunity of the neoadjuvant approach L. Gianni, Milan, I XII Michelangelo Foundation Seminar Milano, October 12, 2012 The opportunity of the neoadjuvant approach
More informationPI3K/mTOR Dual Inhibitor
PI3K/mTOR Dual Inhibitor LY3023414 Courtney KD, et al 1 Drug Discovery Platform: Cancer Cell Signaling A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the
More informationManagement of ErbB2-positive Breast Cancer: Insights from Preclinical and Clinical Studies with Lapatinib
Review Article Jpn J Clin Oncol 2010;40(11)999 1013 doi:10.1093/jjco/hyq084 Advance Access Publication 11 June 2010 Management of ErbB2-positive Breast Cancer: Insights from Preclinical and Clinical Studies
More informationPI3K Background. The SignalRx R & D pipeline is shown below followed by a brief description of each program:
PI3K Background The phosphatidylinositol 3-kinase (PI3K) pathway is a key cell signaling node whose dysregulation commonly results in the transformation of normal cells into cancer cells. The role of PI3K
More informationMetastatic Breast Cancer What is new? Subtypes and variation?
Metastatic Breast Cancer What is new? Subtypes and variation? Anne Blaes, MD, MS University of Minnesota, Division of Hematology/Oncology Director, Adult Cancer Survivor Program Current estimates for metastatic
More informationReviewers' comments: Reviewer #1 (Remarks to the Author):
Reviewers' comments: Reviewer #1 (Remarks to the Author): The authors have presented data demonstrating activation of AKT as a common resistance mechanism in EGFR mutation positive, EGFR TKI resistant
More informationUpdate on Systemic Treatment of Breast Cancer
Update on Systemic Treatment of Breast Cancer Christoph C. Zielinski Clinical Division of Oncology Department of Medicine I and Comprehensive Cancer Center (www.ccc.ac.at) Medical University Vienna - General
More informationOvercoming resistance to endocrine or HER2-directed therapy
Overcoming resistance to endocrine or HER2-directed therapy Jane Lowe Meisel, MD Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute at Emory University 1 Background While most
More informationPI3K/AKT/mTOR Inhibitors in Breast Cancer
PI3K/AKT/mTOR Inhibitors in Breast Cancer Dr Yoon-Sim YAP Division of Medical Oncology, National Cancer Centre Singapore Global Breast Cancer Conference 2015 Outline Overview of PI3K/Akt/mTOR Pathway Rationale
More informationOsamu Tetsu, MD, PhD Associate Professor Department of Otolaryngology-Head and Neck Surgery School of Medicine, University of California, San
Osamu Tetsu, MD, PhD Associate Professor Department of Otolaryngology-Head and Neck Surgery School of Medicine, University of California, San Francisco Lung Cancer Classification Pathological Classification
More informationCyclin E amplification, a novel mechanism of resistance to trastuzumab in HER2 amplified breast cancer Sunday, Apr 18, 2010, 2:25 PM - 2:40 PM
Abstract Print View Page 1 of 1 Presentation Abstract Abstract Number: Presentation Title: Presentation Time: Location: Author Block: 22 Cyclin E amplification, a novel mechanism of resistance to trastuzumab
More informationINNOVAZIONI TERAPEUTICHE IN ONCOLOGIA MEDICA CAGLIARI GIUGNO 2005 Policlinico Universitario - Cagliari LAPATINIB
INNOVAZIONI TERAPEUTICHE IN ONCOLOGIA MEDICA CAGLIARI 23-24 GIUGNO 2005 Policlinico Universitario - Cagliari LAPATINIB Elena Massa CATTEDRA DI ONCOLOGIA MEDICA UNIVERSITA DEGLI STUDI DI CAGLIARI ErbB Inhibition
More informationLa vía PI3K como diana: abordaje y nuevas estrategias en resistencias
La vía PI3K como diana: abordaje y nuevas estrategias en resistencias Ana Maria Gonzalez-Angulo, M.D. Associate Professor Section Chief, Clinical Research and Drug Development Breast Medical Oncology Systems
More informationTargeting PI3 Kinase/AKT/mTOR Signaling in Cancer
Critical Reviews in Oncogenesis, 17(1), 69 95 (2012) Targeting PI3 Kinase/AKT/mTOR Signaling in Cancer Karen E. Sheppard, 1,4 Kathryn M. Kinross, 1 Benjamin Solomon, 1,2,5 Richard B. Pearson, 1,4,5,7*
More informationUpdate on the Management of HER2+ Breast Cancer. Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany
Update on the Management of HER2+ Breast Cancer Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany Outline Treatment strategies for HER2-positive metastatic breast cancer since First
More informationArQule Jefferies Global Healthcare Conference June 2015
ArQule Jefferies Global Healthcare Conference June 2015 1 ArQule Corporate Update Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning
More informationAACR 101st Annual Meeting 2010, Washington D.C. Experimental and Molecular Therapeutics Section 29; Abstract #3855
Investigation of the Growth Inhibitory Activity of the MEK Inhibitor ARRY-162 in Combination with Everolimus in a Variety of KRas and PI3K Pathway Mutant Cancers Brian Tunquist, Tyler Risom, Debbie Anderson,
More informationAmplification of the oncogene HER2 in breast cancer: molecular basis and therapeutic significance
Journal of the Senologic International Society The World Society fo Breast Diseases Volume 1. Issue 2. 2012 REVIEW ARTICLE Amplification of the oncogene HER2 in breast cancer: molecular basis and therapeutic
More informationBreast Cancer Carcinogenesis: Mechanisms and Pathways in Hormone Receptor Positive Disease
Breast Cancer Carcinogenesis: Mechanisms and Pathways in Hormone Receptor Positive Disease 1 Nearly Two-Thirds of Metastatic Breast Cancers Express Hormone Receptors Breast cancer tumors are often classified
More informationNature Medicine: doi: /nm.3559
Supplementary Note 1. A sample alteration report. Each alteration nominated by PHIAL is curated to answer specific fields that are intended to guide physician interpretation. Gene Alteration Patient ID
More information10/15/2012. Inflammatory Breast Cancer vs. LABC: Different Biology yet Subtypes Exist
Triple-Negative Breast Cancer: Optimizing Treatment for Locally Advanced Breast Cancer Beth Overmoyer MD Director, Inflammatory Breast Cancer Program Dana Farber Cancer Institute Overview Inflammatory
More informationInterrogating mtor Inhibition in Patients with HRPC
Interrogating mtor Inhibition in Patients with HRPC Daniel George, John Madden, Andrew Armstrong, Mark Dewhirst, Nancy Major, and Phillip Febbo Divisions of Medical Oncology, Urology, Pathology, Radiology,
More informationArQule CorporateUpdate
ArQule April 2015 1 ArQule CorporateUpdate Safe Harbor This presentation and other statements by ArQule may contain forwardlooking statements within the meaning of the Private Securities Litigation Reform
More informationRationale Design of Combination Therapy in Prostate Cancer: Targeting the AR and PI3K pathways
Rationale Design of Combination Therapy in Prostate Cancer: Targeting the AR and PI3K pathways Brett S Carver, MD Assistant Attending, Department of Surgery/Urology Prostate Cancer Therapeutics: A Changed
More informationSignal Transduction Pathway Smorgasbord
Molecular Cell Biology Lecture. Oct 28, 2014 Signal Transduction Pathway Smorgasbord Ron Bose, MD PhD Biochemistry and Molecular Cell Biology Programs Washington University School of Medicine Outline 1.
More informationPhase II Cancer Trials: When and How
Phase II Cancer Trials: When and How Course for New Investigators August 9-12, 2011 Learning Objectives At the end of the session the participant should be able to Define the objectives of screening vs.
More informationTreatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic Therapy
Women s Empowerment Cancer Advocacy Network (WE CAN) Conference Bucharest, Romania October 2015 Treatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic
More informationPrinciples of Genetics and Molecular Biology
Cell signaling Dr. Diala Abu-Hassan, DDS, PhD School of Medicine Dr.abuhassand@gmail.com Principles of Genetics and Molecular Biology www.cs.montana.edu Modes of cell signaling Direct interaction of a
More informationCell Signaling part 2
15 Cell Signaling part 2 Functions of Cell Surface Receptors Other cell surface receptors are directly linked to intracellular enzymes. The largest family of these is the receptor protein tyrosine kinases,
More informationCrosstalk between Adiponectin and IGF-IR in breast cancer. Prof. Young Jin Suh Department of Surgery The Catholic University of Korea
Crosstalk between Adiponectin and IGF-IR in breast cancer Prof. Young Jin Suh Department of Surgery The Catholic University of Korea Obesity Chronic, multifactorial disorder Hypertrophy and hyperplasia
More information7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview
Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon
More informationRAS Genes. The ras superfamily of genes encodes small GTP binding proteins that are responsible for the regulation of many cellular processes.
۱ RAS Genes The ras superfamily of genes encodes small GTP binding proteins that are responsible for the regulation of many cellular processes. Oncogenic ras genes in human cells include H ras, N ras,
More informationAWARD NUMBER: W81XWH TITLE: An in Vivo shrna-drug Screen to Identify Novel Targeted Therapy Combinations for KRAS Mutant Cancers
AWARD NUMBER: W81XWH-12-1-0420 TITLE: An in Vivo shrna-drug Screen to Identify Novel Targeted Therapy Combinations for KRAS Mutant Cancers PRINCIPAL INVESTIGATOR: Ryan B. Corcoran, M.D., Ph.D. CONTRACTING
More informationRole of the mtor Pathway in Endocrine Therapy- Resistant Breast Cancer
Role of the mtor Pathway in Endocrine Therapy- Resistant Breast Cancer Ana M. Gonzalez-Angulo, M.D. Associate Professor Breast Medical Oncology Systems Biology Sao Paulo, Brazil, 3/2012 PI3K pathway Meric-Bernstam
More informationPhase II Cancer Trials: When and How
Phase II Cancer Trials: When and How Course for New Investigators August 21-23, 2013 Acknowledgment Elizabeth Eisenhauer for some slides! Learning Objectives At the end of the session the participant should
More informationOutline of the presentation
Outline of the presentation Breast cancer subtypes and classification Clinical need in estrogen-positive (ER+) metastatic breast cancer (mbc) Sulforaphane and SFX-01: the preclinical evidence STEM Phase
More informationPIK3CA mutations are found in approximately 7% of
Original Article Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas Juliana Eng, MD,*
More informationProtein kinases are enzymes that add a phosphate group to proteins according to the. ATP + protein OH > Protein OPO 3 + ADP
Protein kinase Protein kinases are enzymes that add a phosphate group to proteins according to the following equation: 2 ATP + protein OH > Protein OPO 3 + ADP ATP represents adenosine trisphosphate, ADP
More informationRecent Update in Management of Breast Cancer: Medical Oncology. Jin Hee Ahn, M.D., PhD. 23-April-2015
2015 GBCC & 4 th IBCS 1/37 Recent Update in Management of Breast Cancer: Medical Oncology Jin Hee Ahn, M.D., PhD. 23-April-2015 Department of Oncology, Asan Medical Center, UUCM, Seoul, Korea 2/37 3/37
More informationCombinations of targeted therapies in oncology an industry view
Combinations of targeted therapies in oncology an industry view Dr Susan Galbraith SVP Head of Oncology imed AstraZeneca WIN 2014 Symposium 23-24 June Paris France Disclosures I am a full time employee
More informationChapter 15: Signal transduction
Chapter 15: Signal transduction Know the terminology: Enzyme-linked receptor, G-protein linked receptor, nuclear hormone receptor, G-protein, adaptor protein, scaffolding protein, SH2 domain, MAPK, Ras,
More informationKevin R. Fox, MD Rena Rowan Breast Center Abramson Cancer Center University of Pennsylvania Perelman School of MedicineR
Kevin R. Fox, MD Rena Rowan Breast Center Abramson Cancer Center University of Pennsylvania Perelman School of MedicineR Treatment of early stage, HER2 positive breast cancer Treatment of early stage,
More information6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017
TARGETING THE TARGETS IN 2017 Primary Care Focus Symposium July 1, 2017 Grace Wang MD I do not have any relevant financial relationships to disclose at this time TARGETING THE TARGETS IN 2017 What are
More informationC. Bourgier, I. Ray-Coquard, J. Provencal, C. Cropet, A.V. Bourcier, V. Delecroix, A. Reynaud-Bougnoux, J. Cretin, T. Bachelot
1 Exploratory Subgroup Analysis of the TAMRAD Phase 2 GINECO Trial Evaluating Tamoxifen (TAM) Plus Everolimus (RAD) vs TAM Alone in Patients With Hormone-Receptor Positive, HER2-Negative Metastatic Breast
More informationManagement of Inflammatory Breast Cancer: Collaboration is the path forward
Management of Inflammatory Breast Cancer: Collaboration is the path forward Massimo Cristofanilli, M.D., F.A.C.P. Professor of Medicine Associate Director of Translational Research and Precision Medicine
More informationWhat is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland
What is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland Outline Early breast cancer Advanced breast cancer Open questions Outline Early breast cancer
More informationFunzionalità, Meccanismi di Escape, Potenziali Targets di Sinergismo Inibitorio. Federica Recine, MD
Studiando il Pathway di mtor Funzionalità, Meccanismi di Escape, Potenziali Targets di Sinergismo Inibitorio Federica Recine, MD Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome,
More informationExpanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer
Expanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer Sara A. Hurvitz, MD, FACP Associate Professor of Medicine University of California Los Angeles Los Angeles, California Trastuzumab
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationAntibody-Drug Conjugates in Glioblastoma Multiforme: Finding Ways Forward
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationCase Study - Informatics
bd@jubilantbiosys.com Case Study - Informatics www.jubilantbiosys.com Validating as a Prognostic marker and Therapeutic Target for Multiple Cancers Introduction Human genome projects and high throughput
More informationTriple Negative Breast Cancer. Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008
Triple Negative Breast Cancer Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008 Triple Negative Breast Cancer 15% 25% Triple Negative 20% HER2+ ER+ Low Grade
More informationOMP-305B83: A Novel, Potent DLL4 & VEGF Targeting Bispecific Antibody for the Treatment Of Solid Tumors
OMP-305B83: A Novel, Potent DLL4 & VEGF Targeting Bispecific Antibody for the Treatment Of Solid Tumors Jakob Dupont MD MA CMO, SVP: OncoMed Pharmaceuticals Adjunct Clinical Faculty: Stanford University
More informationTratamiento neoadyuvante: Enfermedad residual como marcador de resistencia Carlos L. Arteaga, MD Vanderbilt-Ingram Cancer Center Vanderbilt
Tratamiento neoadyuvante: Enfermedad residual como marcador de resistencia Carlos L. Arteaga, MD Vanderbilt-Ingram Cancer Center Vanderbilt University Neoadjuvant (preoperative) therapy Surgery Systemic
More informationDesign of Clinical Trials with Molecularly Targeted Therapies. Gilberto Schwartsmann
Design of Clinical Trials with Molecularly Targeted Therapies Gilberto Schwartsmann What are the basics of clinical trial design? Presented By Jordan Berlin at 2016 ASCO Annual Meeting Advances in molecular
More informationTargeting CDK 4/6. Jee Hyun Kim, M.D., Ph.D. Seoul National University College of Medicine
2016.04.30 GBCC Education Symposium Targeting CDK 4/6 Jee Hyun Kim, M.D., Ph.D. Seoul National University College of Medicine Contents Cyclins -CDKs in cell cycle control CDK 4/6 in breast cancer Preclinical
More informationCohort D Xentuzumab + abemaciclib + fulvestrant (500 mg/month) Key exclusion criteria RP2D-4 NSCLC. Cohort F Xentuzumab + abemaciclib + fulvestrant
A phase Ib trial of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumors, including hormone receptor-positive, HER2-negative breast cancer (plus endocrine therapy) Douglas
More information